Original from: Qiagen
QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.
Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, helping researchers understand which genes are involved in a disease, a biological process or a response to a drug or environmental condition.
IPA, which forms the foundation of IPA Interpret, has over 50,000 citations and a high-quality, manually curated knowledge base. This widely recognized platform structures and integrates causal biomedical relationships between genes, diseases, functions, targets, drugs chemicals, and other objects. With IPA's curated knowledge base, scientists can confidently predict and validate novel target-disease and drug-disease relationships.
By combining this extensive knowledge with advanced analyses and AI algorithms, IPA Interpret now automatically analyzes, compares, and contextualizes complex gene expression datasets available in IPA, identifying key biological processes, pathways, and networks, in a streamlined web-page report.
¡°IPA Interpret is a breakthrough in molecular data analysis, combining the best of human expertise and AI technology,¡± said Dominic John, Vice President, QIAGEN Digital Insights. ¡°Our augmented approach leveraging AI and Natural Language Processing with humans ensures that our customers have trustworthy and quality data with the causal relationships needed to drive AI insights. IPA Interpret embodies this approach and empowers more researchers to uncover deeper insights and make more informed decisions, faster.¡±
One of the standout features of IPA Interpret is its ability to generate comprehensive reports that can be easily shared with colleagues and collaborators. With a simple link, researchers can distribute their findings, fostering collaboration and accelerating the dissemination of scientific knowledge. Additionally, IPA Interpret provides updated graphical representations of key results, enhancing the clarity and impact of the insights.
QIAGEN is continuously integrating AI technology in its QDI portfolio. In early 2024, QIAGEN released an AI-driven biomedical knowledgebase to drive data-driven drug discovery and in late 2023, QIAGEN released an AI-driven enhancement to its market-leading QIAGEN Clinical Insight Interpret product capabilities.
